Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Bydgoszcz – page 46

723 clinical trials in Bydgoszcz, Poland across 6 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Bydgoszcz at a glance
723
clinical trials
  • Research sites6
Type of trial
Recruitment status
Quick filters

723 trials in Bydgoszcz

Open in trial search

Renal cell carcinoma

Not recruiting

Study on Atezolizumab and Cabozantinib for Patients with Advanced Renal Cell Carcinoma After Tumor Progression Post-Immune Checkpoint Inhibitor Treatment

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Hidradenitis

Not recruiting

Study of Lutikizumab compared to placebo in adults and adolescents (age 12 and older) with moderate to severe Hidradenitis Suppurativa

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lutikizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Idiopathic pulmonary fibrosis

Not recruiting

Study on the Effects and Safety of Buloxibutid for Patients with Idiopathic Pulmonary Fibrosis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Buloxibutid
  • Sponsor:Vicore Pharma AB

Cardiac failure acute

Not recruiting

Study of dapagliflozin effects in patients hospitalized with acute heart failure

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin Propanediol Monohydrate
  • Sponsor:The Brigham And Women’s Hospital Inc.

Neurofibromatosis

Not recruiting

Study on the Effect of Food on Selumetinib in Adolescents with Neurofibromatosis Type 1 Plexiform Neurofibromas

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Substances:Selumetinib
  • Sponsor:AstraZeneca AB

Major depression+1

Not recruiting

Study on Aticaprant and Antidepressant for Preventing Relapse in Adults with Major Depressive Disorder and Anhedonia

Investigational
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Aticaprant
  • Sponsor:Janssen Cilag International

Non-small cell lung cancer

Not recruiting

Study of Durvalumab with Chemoradiation Therapy for Patients with Unresectable, Locally Advanced Non-small Cell Lung Cancer

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Renal cell carcinoma+2

Not recruiting

Study on Patient Preference for Subcutaneous Pembrolizumab with Hyaluronidase vs. Intravenous Pembrolizumab in Melanoma, Renal Cell Carcinoma, and Lung Cancer Patients

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Rheumatoid arthritis

Not recruiting

Study Comparing Abatacept and Adalimumab for Adults with Early Rheumatoid Arthritis Not Responding to Methotrexate

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Abatacept
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Renal cell carcinoma

Not recruiting

Study of Nivolumab and Ipilimumab for Patients with Advanced Kidney Cancer and Intermediate or Poor Risk Factors

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Autoimmune demyelinating disease

Not recruiting

Study on the Effects of Satralizumab for Patients with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

Registered drug
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Primary progressive multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Ocrelizumab for Adults with Primary Progressive Multiple Sclerosis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Bydgoszcz

What the registry says about research in the country

01 Respiratory & Infectious Diseases

Innovative clinical trials focusing on respiratory syncytial virus (RSV) and pneumococcal infections in both adults and children. Studies include vaccine development for multiple age groups and assessment of immune responses.

  • RSV and Metapneumovirus Prevention
  • Pneumococcal Vaccine Development
  • COPD Treatment Innovation

Research emphasizes preventive measures and vaccine efficacy across different age groups.

02 Neurological Disorders

Groundbreaking research into neurodegenerative conditions, with particular focus on early intervention strategies for Alzheimer's and Parkinson's disease treatment approaches.

  • Early Alzheimer's Disease
  • Parkinson's Disease Therapeutics
  • Myasthenia Gravis Management

Studies aim to slow disease progression and improve patient outcomes.

03 Autoimmune & Inflammatory Conditions

Comprehensive trials examining new treatments for various inflammatory disorders, including psoriasis, arthritis, and inflammatory bowel diseases.

  • Psoriatic Arthritis
  • Crohn's Disease
  • Atopic Dermatitis

Focus on developing targeted therapies for chronic inflammatory conditions.

Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.